Sertraline (Zoloft) and Black patients

SSRIs as a class have more complex race-specific evidence than cardiovascular drugs. Three themes matter:

• Response rates. Post-hoc analyses of STAR*D (Lesser et al., J Clin Psychiatry 2007) and other large antidepressant effectiveness trials have shown mixed race-based response signals. Some analyses suggest slightly lower remission rates in Black participants treated with citalopram alone; others show no significant difference when confounders (income, insurance continuity, stigma-driven under-reporting) are controlled. The honest summary is that efficacy differences are small at best and largely explained by social factors.
• CYP2D6 and CYP2C19 pharmacogenomics. Sertraline is metabolized mainly by CYP2C19 (and to a lesser degree 2B6 and 3A4). CYP2C19 poor metabolizers — common in Black populations for some allele patterns — may have higher sertraline levels and more side effects at standard doses. Hicks et al. (Clin Pharmacol Ther 2015;98:127–34) summarize CPIC dosing guidance.
• Access and discontinuation. Black adults with depression are less likely to receive any antidepressant treatment, less likely to be referred to psychotherapy, and more likely to discontinue medication early than white adults with comparable diagnoses (Alegría et al., Psychiatr Serv 2008;59:1264–72; Lê Cook et al., Med Care 2014;52:S4–S11). Side-effect counseling, expectation-setting, and cultural-competency of the clinician strongly affect whether a patient stays on the drug long enough to respond.